Merck & Co., Inc. with ticker code (MRK) have now 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $143.60 and $109.33 suggesting an average Analsyt target price of $131.02. Now with the previous closing price of $128.66 and the analysts are correct then we can expect a percentage increase in value of 1.8%. It’s also worth noting that there is a 50 day moving average of $126.82 and the 200 moving average now moves to $114.56. The company has a market cap of 333.65B. The stock price for Affirm Holdings, Inc. is $131.73 USD
The potential market cap would be $339,767,113,772 based on the market consensus.
The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 146.37, revenue per share of $24.22 and a 10.26% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
